On April 22, 2025 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported it will present 18 abstracts, including four oral sessions, showcasing advances in multi-cancer detection and multiomic precision oncology testing enabled by its Guardant Infinity smart liquid biopsy platform at the 2025 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, April 25-30 in Chicago (Press release, Guardant Health, APR 22, 2025, View Source [SID1234652030]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Key data that will be highlighted include:
An oral presentation of performance data for the Shield MCD test, selected for the National Cancer Institute’s Vanguard Study evaluating emerging multi-cancer detection (MCD) technology
Additional oral presentations on methylation-based cancer signal of origin identification, methylation profiling for lung cancer subtyping, and a real-world data analysis of BRAF mutations in non-small cell lung cancer
Analytical validation of Guardant’s new tissue profiling assay with integrated multiomics, showing a high success rate with minimal tissue input and supporting the acceleration of novel biomarker discovery
New methylation-based applications for liquid biopsy, including molecular subtyping of lung and breast cancer, rule-out of actionable genomic mutations, and identification of promoter methylation and MTAP deletions
"We look forward to sharing new data demonstrating the tremendous potential of the Guardant Infinity smart liquid biopsy platform to provide researchers and healthcare providers with a more complete picture of cancer, including genomics, epigenomics and more," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "This multidimensional view of cancer biology is enabling advances in precision oncology ranging from blood-based multi-cancer detection to identification of novel biomarkers that can help bring the next generation of cancer therapeutics to patients sooner."
The full abstracts for Guardant Health and a list of all abstracts being presented at AACR (Free AACR Whitepaper) 2025 can be found on the AACR (Free AACR Whitepaper) website.
For information and updates from the conference, follow Guardant Health on LinkedIn, X (Twitter) and Facebook or visit AACR (Free AACR Whitepaper) booth #1523.
Full List of Guardant Health Presentations
Date and Time (CDT)
Title
Abstract and Poster Section/Board
Guardant Product
Multi-Cancer
Sunday, April 27, 2:00-5:00pm
Analytical validation of a tissue-free epigenomic assay for circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection in early-stage cancer
Abstract #692
Poster Section 29 Poster Board #25
Guardant Reveal
Sunday, April 27, 2:00-5:00pm
Development and characterization of a negative prediction algorithm for actionable mutations utilizing genomic and epigenomic profiling in cfDNA
Abstract #733
Poster Section 31 Poster Board #18
Guardant Infinity
Sunday, April 27, 3:00-5:00pm
A novel methylation-based classifier to identify cancer signal of origin using blood-based testing
Oral Minisymposium Session
Abstract #6365
Guardant Infinity Screening
Monday, April 28, 9:00am-12:00pm
Inferring immune and tissue cell type contributions to cell-free DNA (cfDNA) with a DNA methylation assay
Abstract #1951
Poster Section 28
Poster Board #19
Guardant Infinity
Monday, April 28, 9:00am-12:00pm
Detection of clinically actionable somatic variants in post-operative samples from patients with molecular residual disease
Abstract #1953
Poster Section 28
Poster Board #21
Guardant Reveal
Monday, April 28, 9:00am-12:00pm
Blood-based mapping of the personalized tumor epigenomic landscape
Abstract #1955
Poster Section 28 Poster Board #23
Guardant Infinity
Monday, April 28, 2:00-5:00pm
Analytical validation of cancer gene promoter methylation detection in cfDNA liquid biopsy assay
Abstract #3255
Poster Section 29 Poster Board #20
Guardant Infinity
Tuesday, April 29, 2:30-4:30pm
Evaluation of a plasma cell-free DNA methylation-based multi-cancer detection test
Oral Minisymposium
Session
Abstract #6425
Shield MCD Test
Tuesday, April 29, 2:00-5:00pm
A tumor-specific, methylation-based algorithm to identify MTAP gene deletions via tissue-free circulating tumor DNA
Abstract #5924
Poster Section 30 Poster Board #16
Guardant Infinity
Tuesday, April 29, 2:00-5:00pm
Analytical validation of a robust, integrated multiomics tissue assay powered by the Guardant Infinity platform
Abstract #5935
Poster Section 30 Poster Board #27
Guardant Infinity
Tuesday, April 29, 2:00-5:00pm
Landscape of epigenomic tumor fraction in large pan-cancer cfDNA cohort
Abstract #5936
Poster Section 30 Poster Board #28
Guardant Infinity
Wednesday, April 30, 9:00am-12:00pm
Analytical validation of a new plasma-only bioinformatics classifier to identify variants from clonal hematopoiesis (CH) in cfDNA liquid biopsy assays
Abstract #6603
Poster Section 9 Poster Board #10
Guardant Infinity
Lung
Sunday, April 27, 3:00-5:00pm
Non-invasive cell free DNA (cfDNA) methylation profiling for accurate proportional quantification of lung cancer subtypes
Oral Minisymposium
Session
Abstract #1142
Guardant Infinity
Tuesday, April 29, 9:00am-12:00pm
EGFR PACC mutations occur more frequently as compound mutations with better responses to EGFR TKIs
Abstract #4594
Poster Section 30 Poster Board #14
Guardant360
Tuesday, April 29, 2:30-4:30pm
Unveiling the potent anti-tumor activity and underlying mechanism of action of the novel pan-RAF inhibitor exarafenib in BRAF-mutated NSCLC
Oral Minisymposium Session
Abstract #6389
Guardant Inform
Breast
Monday, April 28, 2:00-5:00pm
Pre- and post-operative analysis of circulating tumor DNA in patients with breast cancer treated with neoadjuvant therapy using a tissue-free, methylation-based approach
Abstract #3360
Poster Section 32 Poster Board #30
Guardant Reveal
Monday, April 28, 2:00-5:00pm
Liquid based methylation profiling for quantification of breast cancer subtypes
Abstract #3247
Poster Section 29 Poster Board #12
Guardant Infinity
Colorectal
Monday, April 28, 9:00am-12:00pm
Employing joint modeling to support clinical interpretation of ctDNA dynamics during the treatment of advanced colorectal cancer
Abstract #2481
Poster Section 41 Poster Board #2
Guardant Inform